Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

LabCorp Enters Into License Agreement with Sequella for use of B-SMART™ Technology to develop Rapid Tuberculosis Antimicrobial



  LabCorp Enters Into License Agreement with Sequella for use of B-SMART™
  Technology to develop Rapid Tuberculosis Antimicrobial Susceptibility Test

Business Wire

ROCKVILLE, Md. -- October 22, 2012

Sequella Inc., a clinical-stage pharmaceutical company developing novel
antibiotics to treat life-threatening infectious diseases, licensed its
B-SMART™ technology to Laboratory Corporation of America® Holdings (LabCorp)
(NYSE: LH) to allow LabCorp to develop a new laboratory-based antibiotic
susceptibility assay for Mycobacterium tuberculosis and to commercially use
the assay in the United States. The assays  that LabCorp will develop using
B-SMART™ technology will combine nucleic acid testing with phage-based
technology to accurately and quickly identify any resistance of M.
tuberculosis clinical isolates to antitubercular antibiotics, regardless of
whether the resistance genotype is known. Financial terms of the agreement
were not disclosed. Sequella retains all rights to commercialize B-SMART™
technology worldwide for indications other than tuberculosis, and for
territories other than the United States for tuberculosis.

Nucleic acid-based diagnostics are well established in laboratory medicine,
and many are used to screen for infectious diseases, resulting in a $1.1
billion industry in the United States. The B-SMART™ technology is compatible
with any nucleic acid detection system, can be used to develop tests that
detect resistance to any drug, and can provide results in hours.

“We are delighted to sign the first partnership for our B-SMART™ technology
with LabCorp, an industry leader in central laboratory testing in the United
States,” commented Dr. Carol A. Nacy, CEO of Sequella. “We look forward to a
successful collaboration and a timely introduction by LabCorp of a new assay
that can facilitate appropriate drug selection by physicians treating
tuberculosis in this country.”

About B-SMART™

B-SMART™ technology enables nucleic acid-based systems to measure bacterial
viability and drug resistance. By combining the accuracy of functional drug
susceptibility assays with the speed and sensitivity of molecular diagnostics,
the assays that LabCorp will develop using B-SMART™ technology can accurately
and simultaneously report microbial identification and drug susceptibility in
a matter of hours or days, depending upon the bacterial species. B‐SMART™ is 
the first rapid nucleic acid‐based technology that can detect drug resistance
without any prior knowledge of the  genes or mutations that confer drug
resistance.

About Sequella

Sequella is a clinical stage pharmaceutical company focused on identifying,
developing, and commercializing novel antibiotics to treat infectious
diseases, particularly those for whom drug resistance is a growing problem.
The company leverages its global influence, R&D platforms, and infectious
disease expertise to proactively address emerging health threats. Through
focused execution, clear commercialization pathways, and strategic
partnerships, Sequella intends to commercialize a broad product portfolio
designed to treat global health threats with significant market opportunity.

Forward-Looking Statement

This press release contains forward-looking statements that are subject to
risks and uncertainties, and includes statements that are not historical
facts. Actual results could differ significantly from results discussed.
Sequella disclaims any intent or obligation to update forward-looking
statements, except as required by law.

Contact:

Sequella
Alan S. Klein
Executive Vice President, Corporate Development
301-762-7776
alanklein@sequella.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement